Latest news
Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLiveHCPLive · Fri, 07 Aug 2026 23:10:36 GMTOral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 16:04:43 GMTDrug-Induced Autoimmune Inflammatory Myositis in a Patient with Psoriatic Arthritis Receiving Biologic Therapy: A Case Report - EMJEMJ · Fri, 07 Aug 2026 15:22:52 GMTObesity May Influence Biologic Response in PsO, With Effects Varying by Drug Class - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 13:04:42 GMTTreating Adolescent Plaque Psoriasis: Tolerability and Adherence - HCPLiveHCPLive · Fri, 07 Aug 2026 12:11:05 GMTExploring the Efficacy and Durability of Oral Agents in Psoriasis - HCPLiveHCPLive · Fri, 07 Aug 2026 12:01:05 GMTPerspectives on Psoriatic Arthritis - Everyday HealthEveryday Health · Thu, 06 Aug 2026 22:36:57 GMT3 Ways Psoriasis Can Affect Your Social Life—and How to Cope - glamour.comglamour.com · Thu, 06 Aug 2026 14:52:02 GMT